PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of “Moderate Buy” by Brokerages
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
US FDA puts partial clinical hold on PepGen's muscle disease drug trial
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
PepGen Announces Regulatory Updates on FREEDOM2
PepGen to Participate in the Leerink Global Healthcare Conference
PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Recommendation of “Moderate Buy” from Analysts
PepGen (PEPG) Expected to Announce Earnings on Monday
PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of “Moderate Buy” by Brokerages
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)
Analysts Set PepGen, Inc. (NASDAQ:PEPG) Target Price at $10.00
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
PepGen to Participate in Upcoming Investor Conferences
PepGen: DMD Discontinued, Ways To Go With DM1
Insiders Snap Up $54M in Biotech and Offshore Driller Stocks
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles
PepGen Announces Pricing of $100 Million Public Offering
PepGen Announces Proposed Public Offering
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
Kuehn Law Encourages Investors of PepGen Inc. to Contact Law Firm
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
Faruqi & Faruqi Reminds PepGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 - PEPG